arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Dyne Therapeutics, Inc.

DYN

$26.25 ▲ +0.37 (+1.41%) at close

8 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Neutral

auto_awesome

Analytical Summary

Dyne Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -33.0% ↗

FCF / Share —

Trailing P/E —

Price / Book 4.5x

FCF Yield —

Debt / Equity 0.15

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-446.21M

↓ -40.6% —

Long-Term Debt Long-term obligations

$148.92M

— —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
EPS Growth YoY (%)	-3.0% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	14.7% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-22.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-10.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-40.6% Weak ↓ Weak Declining Year-over-year change in net income	-34.5% Weak ↑ Weak Improving Year-over-year change in net income	-40.4% Weak ↑ Weak Improving Year-over-year change in net income	-12.6% Weak ↑ Weak Improving Year-over-year change in net income	-151.2% Weak Weak Year-over-year change in net income	-300.0% Weak Weak Year-over-year change in net income	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
FCF / Net Income (x)	0.91x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-33.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-43.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-209.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-53.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-32.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-13.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-77.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-39.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-49.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-146.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-55.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-35.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-16.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-84.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-45.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-406%)	-50.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-436%)	-258.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1823%)	-66.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-544%)	-40.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-370%)	-17.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-216%)	-105.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-806%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Debt to Equity (x)	0.15x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-74%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—	—	—	—
Interest Coverage (x)	-107.90x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	—
Net Debt (USD)	$-744.45M	$-435.45M	$-121.63M	$-172.15M	$-200.82M	$-300.85M	$-14.63M	—
Debt / EBITDA (x)	-0.32x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—

📊 What does each share earn? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Basic EPS, GAAP (USD)	$-3.47	$-3.37	$-3.95	$-3.23	$-2.93	—	—	—
Book Value per Share (USD)	$5.89	$6.16	$1.49	$4.54	$7.14	$7.60	$5.43	—
Tangible Book Value per Share (USD)	$5.89	$6.16	$1.49	$4.54	$7.14	$7.60	$5.43	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$1.08B	$617.02M	$78.28M	$237.51M	$353.67M	$338.12M	$12.40M	—
LT Debt (USD)	$148.92M	$0.00	—	—	—	—	—	—
Total Equity (USD)	$972.13M	$629.84M	$91.29M	$252.36M	$368.20M	$342.37M	$14.04M	$-4.88M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Depreciation Expense (USD)	$2.05M	$1.67M	$1.67M	$1.68M	$1.09M	$700.00K	$271.00K	—
Net Income, GAAP (USD)	$-446.21M	$-317.42M	$-235.94M	$-168.10M	$-149.29M	$-59.44M	$-14.86M	—
Operating Cash Flow (USD)	$-403.21M	$-292.37M	$-188.16M	$-153.65M	$-119.56M	$-46.51M	$-11.83M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 31 quarters

Dyne Therapeutics, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare DYN with peers